Ensysce Biosciences ENSC
NASDAQ ENSC
$0.51 +0.01 (+1.62%)
As of: Oct 21, 2026 · 10:08 AM EDT

Ensysce Biosciences (ENSC) Convertible Debt (2020 - 2021)

Updated

Ensysce Biosciences (ENSC) posted Convertible Debt of $5 million for Q4 2021, up 646.0% from $670,262 a year earlier and unchanged from the prior quarter.

Analysis

Ensysce Biosciences (ENSC) Convertible Debt (2020 - 2021) Analysis & Trends

Since Q1 2020, Ensysce Biosciences has reported Convertible Debt for 4 quarters.

  • In prior years, Ensysce Biosciences' Convertible Debt was $670,262 in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,129.39 Bn 1,097.98 Bn 19.71 Bn
2 Johnson & Johnson 615.68 Bn 534.21 Bn 17.26 Bn
3 AbbVie 505.77 Bn 478.89 Bn 12.70 Bn
4 Merck 366.50 Bn 320.88 Bn 12.21 Bn
5 Novartis Ag 297.33 Bn 261.32 Bn 11.24 Bn
6 Astrazeneca 261.02 Bn 234.71 Bn 12.86 Bn
7 Amgen 235.47 Bn 190.87 Bn 7.24 Bn
8 Gilead Sciences 189.20 Bn 163.40 Bn 6.22 Bn
9 Pfizer 170.20 Bn 116.85 Bn 10.94 Bn
10 Ensysce Biosciences 1.30 Mn -9.95 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 5.00 Mn
Sep 30, 2021 5.00 Mn
Dec 31, 2020 670,262.00
Mar 31, 2020 1.00 Mn
API Access

Ensysce Biosciences Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=ENSC&period=max&api_key=YOUR_API_KEY